MannKind Corp
MNKDMannKind Corporation is a public biopharmaceutical company pioneering inhaled therapeutic delivery systems, primarily for diabetes and pulmonary diseases. Its flagship product, Afrezza, is an FDA-approved rapid-acting inhaled insulin that offers a needle-free alternative for prandial insulin. The company leverages its proprietary Technosphere® platform to develop novel inhaled formulations, with a pipeline targeting endocrine disorders and orphan lung conditions like pulmonary arterial hypertension and pulmonary fibrosis. MannKind's strategy combines commercial execution of Afrezza with pipeline advancement through internal R&D and strategic partnerships.
MNKD · Stock Price
Historical price data
AI Company Overview
MannKind Corporation is a public biopharmaceutical company pioneering inhaled therapeutic delivery systems, primarily for diabetes and pulmonary diseases. Its flagship product, Afrezza, is an FDA-approved rapid-acting inhaled insulin that offers a needle-free alternative for prandial insulin. The company leverages its proprietary Technosphere® platform to develop novel inhaled formulations, with a pipeline targeting endocrine disorders and orphan lung conditions like pulmonary arterial hypertension and pulmonary fibrosis. MannKind's strategy combines commercial execution of Afrezza with pipeline advancement through internal R&D and strategic partnerships.
Technology Platform
Proprietary Technosphere® platform for inhaled dry powder delivery, enabling rapid systemic absorption of peptides, proteins, and small molecules via the lungs. It combines a unique FDKP-based powder formulation with the portable, breath-actuated Dreamboat® inhaler.
Pipeline
60| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Afrezza plus One Drop | Premium | Diabetes Mellitus, Type 2 | Approved | |
| Technosphere insulin | Diabetes Mellitus, Type 1 | Approved | |
| Afrezza + insulin degludec + Rapid-acting Insulin Analog + B... | Diabetes Mellitus, Type 1 | Approved | |
| Afrezza (insulin human) Inhalation Powder + insulin degludec | Type 1 Diabetes | Approved | |
| Technosphere® Insulin with MedTone C Inhaler + Technosphere ... | Type 1 Diabetes Mellitus | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
MannKind competes with large pharma in diabetes (Novo Nordisk, Eli Lilly, Sanofi) with its unique inhaled insulin, and in pulmonary hypertension with its partner United Therapeutics against other prostacyclin therapies. Its primary differentiation is the non-invasive, rapid-delivery Technosphere platform, though it faces challenges in changing established treatment paradigms and competing with well-resourced rivals.